Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim N Chi

Showing results (21-30 of 234) with videos related to

Pageof 24
Sort By:
Nature Reviews. Urology|December 17, 2014
Targeting heat shock proteins in metastatic castration-resistant prostate cancerArun A Azad, Amina Zoubeidi, Martin E Gleave, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 12, 2014
Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancerRobert R Zielinski, Arun A Azad, Kim N Chi, et al.
BJU International|October 4, 2018
DNA repair defects in prostate cancer: impact for screening, prognostication and treatmentEvan W Warner, Steven M Yip, Kim N Chi, et al.
European Urology|July 15, 2014
Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patientsArun A Azad, Bernhard J Eigl, R Nevin Murray, et al.
BJU International|July 20, 2016
Liquid biopsy: ready to guide therapy in advanced prostate cancer?Miriam Hegemann, Arnulf Stenzl, Jens Bedke, et al.
American Journal of Clinical Oncology|February 8, 2006
A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancerAnna Tinker, Eric Winquist, Christina Canil, et al.
The Journal of Urology|November 11, 2005
Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British ColumbiaAbdulwahab J Al-Tourah, Nevin Murray, Chris Coppin, et al.
The Journal of Urology|June 17, 2008
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancerKim N Chi, Joseph L Chin, Eric Winquist, et al.
Practical Radiation Oncology|January 15, 2019
A Population-Based Study of Palliative Radiation Therapy for Bone Metastases in Patients Dying of Prostate CancerChan-Kyung Jane Cho, Katherine Sunderland, Tom Pickles, et al.
Cancer Medicine|October 25, 2013
Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsenBrent Blumenstein, Fred Saad, Sebastien Hotte, et al.
Pageof 24

Showing results (21-30 of 234) with videos related to

Sort By:
Pageof 24
Nature Reviews. Urology|December 17, 2014
Targeting heat shock proteins in metastatic castration-resistant prostate cancerArun A Azad, Amina Zoubeidi, Martin E Gleave, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 12, 2014
Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancerRobert R Zielinski, Arun A Azad, Kim N Chi, et al.
BJU International|October 4, 2018
DNA repair defects in prostate cancer: impact for screening, prognostication and treatmentEvan W Warner, Steven M Yip, Kim N Chi, et al.
European Urology|July 15, 2014
Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patientsArun A Azad, Bernhard J Eigl, R Nevin Murray, et al.
BJU International|July 20, 2016
Liquid biopsy: ready to guide therapy in advanced prostate cancer?Miriam Hegemann, Arnulf Stenzl, Jens Bedke, et al.
American Journal of Clinical Oncology|February 8, 2006
A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancerAnna Tinker, Eric Winquist, Christina Canil, et al.
The Journal of Urology|November 11, 2005
Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British ColumbiaAbdulwahab J Al-Tourah, Nevin Murray, Chris Coppin, et al.
The Journal of Urology|June 17, 2008
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancerKim N Chi, Joseph L Chin, Eric Winquist, et al.
Practical Radiation Oncology|January 15, 2019
A Population-Based Study of Palliative Radiation Therapy for Bone Metastases in Patients Dying of Prostate CancerChan-Kyung Jane Cho, Katherine Sunderland, Tom Pickles, et al.
Cancer Medicine|October 25, 2013
Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsenBrent Blumenstein, Fred Saad, Sebastien Hotte, et al.
Pageof 24